Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Gynecologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Mesothelioma 1Breast Neoplasms 1

Interventions

pembrolizumab 6belinostat 2Pemetrexed 2Cyclophosphamide 2Cisplatin 2Carboplatin 2tocilizumab 1sargramostim 1ribociclib 1rebastinib 1enzalutamide 1entinostat 1durvalumab 1cemiplimab 1avelumab 1atezolizumab 1abemaciclib 1Valacyclovir 1Surgical Procedures, Operative 1Sorafenib 1Sirolimus 1Quality of Life 1Psychiatric Rehabilitation 1Polymerase Chain Reaction 1Plicamycin 1Patient Reported Outcome Measures 1Nivolumab 1Molecular Diagnostic Techniques 1Midazolam 1Microarray Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Breast Neoplasms × rebastinib × Other solid neoplasm × Clear all
NCT03717415 2024-12-27

A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
70 enrolled 24 charts
BreastGynecologicOther solid neoplasmThoracic

Breast Neoplasms, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡